Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
Applied DNA Sciences (NASDAQ:APDN) announced it will release its fourth quarter and fiscal year 2024 financial results after market close on December 17, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Applied DNA Sciences (NASDAQ:APDN) announced it will release its fourth quarter and fiscal year 2024 financial results after market close on December 17, 2024. The company will host a conference call and webcast for investors on January 9, 2025, at 4:30 p.m. ET, which will include an update on its GMP manufacturing facility build-out. The presentation will be accessible via webcast and conference call, with replay options available for 7 days following the event. An accompanying slide presentation will be available on the company's investor relations website.
Positive
- GMP manufacturing facility expansion indicates business growth investment
Negative
- Delayed earnings discussion - 23 days gap between results release and conference call
Details
News Market Reaction – APDN
The recorded move for APDN in the trading session of this news was +12.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.
The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.
Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ET
Dial In:
Domestic callers (toll free): 844-887-9402
International callers: 412-317-6798
Canadian callers (toll free): 866-605-3852
Live webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=3UkskFxG
A replay of the conference call will be available for 7 days following the conclusion of the call:
Replay for domestic callers (toll free): 877-344-7529, replay access code 7896562
Replay for international callers: 412-317-0088, replay access code 7896562
Replay for Canadian callers (toll free): 855-669-9658, replace access code 7896562
An accompanying slide presentation will be embedded in the webcast (live and replay) and can be accessed under the ‘Company Events' section of the Applied DNA investor relations website at https://investors.adnas.com/news-events/company-events/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and, (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
For additional information:
Investor Relations: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: https://investors.adnas.com/
SOURCE: Applied DNA Sciences, Inc.
View the original press release on accesswire.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.